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Summary 
After v-H-ms expression, the interleukin 3 (IL-3)-dependent PB-3c mast cells progress in vivo 
to two different classes of IL-3 autocrine tumors. Class I tumors show a germline configuration 
of the IL-3 gene and represent more than 90% of tumors analyzed so far. Somatic cell fusion 
of class I tumor lines with the nontumorigenic parental PB-3c resulted in loss of oncogenic IL-3 
expression by a posttranscriptional  mechanism with concomitant tumor suppression. Class II 
tumors arise rarely and contain an insertion in one IL-3 allele. This alteration was linked to enhanced 
IL-3 gene transcription.  For one tumor, the insertion was shown to be an endogenous retroviral 
element (intracisternal A-particle).  Cell hybrids of class II tumors with PB-3c remained IL-3 
independent, expressed IL-3, and formed tumors rapidly. These results suggest that the v-H-ras 
oncogene synergizes with a recessive and a dominant lesion in class I and II tumors, respectively, 
both of which lead to the autocrine production of IL-3. 
T 
umorigenesis  is  viewed  as  a  multistep  process  with 
sequential acquisition of genetic lesions described as dom- 
inant gain-of-function and recessive  loss-of-function (1). Con- 
stitutive activation of ras proto-oncogenes by point mutations 
represents the former type and has been detected in numerous 
human malignancies including leukemias (2-4). As a GTP/ 
GDP binding protein, p21 ras is thought to function analo- 
gously to other G proteins in the context of signal transduc- 
tion (5). Upon stimulation of hemopoietic ceils with IL-2, 
IL-3, GM-CSF, or via the TCR, inactive GDP-p21 ras is con- 
verted to the activated GTP state by GDP-GTP exchange (6, 
7). The GTPase-activating proteins such as GAP and NF-1 
counter-regulate by increasing the low intrinsic GTPase of 
p21 ras (8). Upon GTP hydrolysis, p21 ras returns to the in- 
active GDP state thereby completing the ras activation cycle. 
Although the immediate effector molecule(s) is still elusive, 
recent evidence places ras upstream of a kinase cascade in- 
cluding c-raf, kinases of MAP kinase, and the ribosomal $6 
kinase p90 to transmit signals to the nucleus (9). Since onco- 
genic point mutations lock p21 in the active GTP state (2), 
ras transformation is thought to result from the constitutive 
activation  of signaling  pathways.  However,  as  shown ex- 
perimentally in transfection  assays, activating  mutations in 
ras oncogenes alone are not sufficient to induce malignant 
transformation, but require further cooperating alterations 
(2, 10, 11). This agrees well with the detection of activating 
ras mutations in some still preneoplastic conditions,  such as 
the myelodysplastic syndrome (12). Conversely, suppression 
of ras oncogene-transformed tumor cells by cell fusion or 
DNA transfection has been shown to operate without affecting 
the expression of the oncogene (11, 13-16). Although the 
biochemical aspects of p21 ras and its modulator molecules 
become more defined, the interplay of ras with complementing 
alterations in oncogenic transformation is not fully understood. 
To investigate the role of ras in hemopoietic malignancy, 
we have focused on a murine tumor model, in which estab- 
lishment of an autocrine IL-3 loop is the hallmark of tumors 
generated from the IL-3-dependent mast cell line PB-3c in 
response to v-H-ras oncogene expression (17). Work in our 
and other laboratories (18-20) has shown that primary mast 
cells can be a physiological source of IL-3 and other cytokines 
after immunological stimulation via IgE receptors. This re- 
sponse can be mimicked pharmacologically by treatment with 
calcium ionophores. In PB-3c mast cells, IL-3 expression by 
calcium ionophore appears to result from posttranscriptional 
stabilization of a constitutive IL-3 transcript  (21). After the 
removal of the stimulus, negative control resumes by rapidly 
degrading the IL-3 mRNA. This physiological response is 
altered by ras oncogenes. In the presence of oncogenic ras, 
IL-3 hyperinduction by calcium ionophores and slowed-down 
decay of IL-3 mRNA after removal of the inducer, was ob- 
served (22, 23). Oncogenic IL-3 expression  in autocrine tumor 
lines might thus result from escape from negative control 
either by alterations in the IL-3 gene or by loss of trans-acting 
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somatic cell fusion. When somatic cell hybrids between the 
tumor cells and the nontumorigenic parental PB-3c  were 
formed, downregulation of IL-3 expression and partial tumor 
suppression was observed (16). In this report, we present evi- 
dence that oncogenic induction of IL-3 expression in auto- 
crine mast cell tumors can in fact involve two different mech- 
anisms. Whereas the more frequent alteration is recessive in 
somatic cell fusion, the other behaves dominantly and shows 
enhanced IL-3 gene transcription linked to the insertion of 
an endogenous retroviral element. 
Materials and Methods 
Cell Lines and Tissue Culture.  PB-3c  is a cloned, IL-3-depen- 
dent,  nontumorigenic mast cell line from murine bone marrow 
(24). The V2 line was obtained by ZIP-ras-neo infection of PB-3c. 
The IL-3-producing, autocrine tumor lines V2D1 and V4D6 have 
been described (17). 8V4-T12, 15V4-ST2, 22V4-T1, and K56VT 
are tumor lines derived from inoculation with the ZIP-ras-neo-in- 
fected PB-3c subclones 8V4, 15V4, 22V4 (23), and K56V (Ban- 
holzer, g., unpublished data). PB-3c H is a hygromycin B-resis- 
tant derivative of PB-3c selected after infection with the ZH2 
retrovirus (Muser, J., unpublished data). All cell lines were cul- 
tured in IMDM containing 10% (vol/vol) of FCS, penicillin (100 
U/ml), streptomycin (100 #g/ml), and 50 #g 2-ME. Saturating 
amounts of conditioned medium from the IL-3-producing X63- 
raiL-3 line (25) were added to IMDM for growth of the IL-3-de- 
pendent cell  lines. Hybrid lines  were generated  by polyethylene  glycol 
fusion and hygromycin/G418 selection in the presence of Ib3 as 
described (16). The DNA content of the hybrid cells was com- 
pared with the parental cells  by FACS  |  analysis  (Becton Dickinson 
& Co., Mountain View, CA) using ethidium bromide or propidium 
iodide staining and found to contain the double DNA content 
(results not shown). 
Northern Blot Analysis.  5 x  107 cells were harvested and total 
KNA was extracted (26). From 400/~g of total RNA, a mRNA- 
enriched preparation was  obtained by single passage through 
oligo-dT cellulose and precipitated, followed  by electrophoresis in 
1.1% (g/vol) agarose 0.66 M formaldehyde gel in MOPS buffer 
pH 5.9 (27), blotting,  and hybridization as described previously 
(23).  The  Ib3  probe was  generated by in  vitro  transcription 
(Boehringer Mannheim, Rotkreuz, Switzerland)  from a pSP6-vector 
containing a 398-bp II,3 cDNA fragment (28). IL-6  cDNA probe, 
generously provided by Dr.  J.  vanSnick (Ludwig-Institute  for 
Cancer, Brussels, Belgium) and the chicken 3-actin probe (0.57-kb 
PstI fragment) were labeled  using a random-priming  kit (Boehringer 
Mannheim). Quantitation  of Ib3 mRNA levels, and normaliza- 
tion to actin levels were done using a phosphoimager (Molecular 
Dynamics, Sunnyvale, CA). 
Southern Blot Analysis.  Preparation  and overnight digestion of 
total  genomic DNA,  electrophoresis separation, transfer onto 
nitrocellulose  membranes (Schleicher  & Schuell, Inc., Keene, NH), 
hybridization to the 1.9-kb HindlII fragment of the genomic Ib3 
gene subcloned from the 8.6-kb EcoRI fragment (29) and labeled 
by random priming, was done according to standard procedures. 
Nuclear Run-on Analysis.  Nuclei  were isolated from 107 of the 
indicated cells and stored at -70~  transcription  reactions at 26~ 
isolation of 32P-labeled KNA (30), hybridization to the indicated 
denatured DNA probes in 50% formamide 5 x  SSC 0.1% SDS 
at 50~  and washing were done as described  in detail  elsewhere (22). 
Inverse PCR and DNA Sequencing.  Two independent genomic 
DNA preparations (5 #g) of the V4D6 tumor line were digested 
overnight with HindIII. After phenol extraction and precipitation, 
a ligation reaction at a DNA concentration of 10 ng/ml was set 
up overnight at room temperature using T4-DNA  ligase. After 
inactivation  at 65~  for 10 min, the sample was digested  with ApaI 
for 5 h before heat inactivation at 65~  Using 50 ng of DNA, 
a PCK reaction was performed in 100/~1 overlayed  with para~n, 
using 20 pmoles of  the primers M422 5'-CCTCCATAGCAAACC- 
ACAAAC-Y and M423 5'-ACCACCAGCATCCACACCATG-Y, 
and 2.5 U of AmpliTaq (Perkin-Elmer Cetus, Norwalk, CT) in 
10 mM Tris-HC1, pH 8.3, 50 mM KC1, 2.5 ram MgC12, 200 #M 
dNTP, for 35 cycles at 95~  for 1 rain, 60~  for 2 rain, and 72~ 
for 3 min. After phenol extraction and precipitation, two major 
bands of 1.9 and 0.5 kb were separated on a 0.7% low-melting 
agarose electrophoresis  gel. The 0.5-kb band was excised  and ligated 
blunt-ended into the pSK+Bluescript vector cut with Sinai. Two 
independent inserts corresponding to each DNA preparaton were 
sequenced in both directions  using the Sequenase  |  kit (United States 
Biochemical, Cleveland, OH). 
Cell Proliferation and Viability.  Proliferation  and viability of  cells 
in the presence and absence of Ib3 was monitored by the MTT 
method (31), by [3H]thymidine incorporation, or by trypan blue 
color exclusion, where indicated. 
Tumor Formation.  To analyze  tumor formation and latency,  ceils 
were washed twice in ice-cold PBS and 10  s or 106 cells/animal 
were injected subcutaneously into 8-12 wk-old female syngeneic 
DBA/2 mice. Mice were examined twice per week for tumor for- 
mation up to 42 wk. 
Results 
IL-3 Gene Rearrangement Distinguishes Two Tumor Classes 
with Autocrine IL-3 Loop.  Upon progression to tumor cells 
in syngeneic animals, v-H-ras-expressing PB-3c cells change 
from an IL-3-dependent to an IL-3-producing autocrine state. 
In this ongoing study in our laboratory, the IL-3 gene locus 
was analyzed in over 40 independently formed tumors by 
Southern blot to detect potential alterations. The majority, 
however, showed a germline configuration like the precursor 
cell PB-3c. So far, only four tumor lines showed a detectable 
alteration of one IL-3 allele. As shown here by hybridization 
with a probe containing the IL-3 promoter and part of the 
first exon, the unaltered IL-3 gene is detected in PB-3c  or 
a ZIP-ras-neo-infected  subclone R56V as a single band of 1.9 
kb after digestion with HindlII (Fig.  1, lanes  1 and 3) or 
of 6.6 kb with SphI, respectively (Fig. 1, lanes 2 and 4). Three 
tumor lines without detectable alterations such as V2D1, 15V- 
T2, and 8V4-T12 were termed class I (Fig.  1, lanes 5-10), 
whereas tumor lines with one rearranged allele, apparent as 
two bands in the SphI digestion, such as tumor lines V4D6, 
K56VT, and the 22V4-T1, were termed class II tumors (Fig. 
1, lanes  12,  14,  and 16). The weaker intensity of the rear- 
ranged allele of 12 kb in 22V4-T1  is compatible with one 
altered and three nonrearranged alleles, as chromosome typing 
has  indicated  a  near  tetraploidy  for  the  IL-3-dependent 
precursor clone 22  (data not shown). With respect  to the 
occurrence of the rearrangement, it is interesting to note that 
K56VT and 22V4-T1 are the only two tumors obtained from 
infected PB-3c subdones R56V and 22V4 in 25 inoculation 
experiments with 5  x  106 or 107 cells injected.  The injected 
subclones express v-H-ras because of infection with the ZIP- 
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of the IL-3  gen~ DNA was prepared 
from the indicated cells, digested 
with HindlII (odd numbers) or SphI 
(even numbers) and hybridized to 
the genomic 1.9-kb HindlII frag- 
ment of Ib3 encompassing the pro- 
motet region up to the exon 1. Lanes 
(1 and 2) PB-3c; (3 and 4) R56V, 
a v-H-ms  expressing  subdoue of PB- 
3c; (5 and 6) V2D1; (7 and 8) 15V- 
T2; (9 and 10) 8V4-T12; (11 and 12) 
R56V'I~ (13 and 14) V4D6; (15 and 
16) 22V4-T1. 
I  i00 
<- (-252) IL-3  U3-rAaion->  GRg  gnhancarl  Z-DNA  * 
V4D6  gtgggaggaagTOTTGGGAGC  CGCCCCCACA  TTCACCGTTA  CAAGATGGCG  CTGACATCCT  GTGTTCTAAG  TGGTAAACAA  ATAATCTGCG  CATGTGCCAA  GGGTATCTTA 
WEHI3B  .............  C  ...................................................................................... 
ANGI  .............  G  ................................  .  G  .................................................... 
MOS  .............  G  .............  G  ........................................................................ 
101  *  CRE  CAAT  TATA  2 00 
V4D6  TGACTACTTG  TGCTCTGCCT  TCCCCGTGAC  GTCAACTCGG  CCGATGGGCT  GCAGCCAATC  AGGGAGTGAC  ACGTCCGAGG  CGAAGGAGAA  TGCTCCTTAA 
WEHI3B  .................................................................................................... 
ANGI  .................................................................................................... 
MOS  .....................................  .  .-  G-CGAT ...................................................... 
201  R- rn~'l esn->  DolvA  304 
V4D6  GAGGGACGGG  G.TTTCGTTT  TCTCTCTCTC  TTGCTTCTTG  CTCTCTTGCT  TCTTGCTCTC  TTGCTTCCTG  CACCCTGGCT  CCTGAAGATG  TAAGAAATAA  AGCTT 
WEHI3B  ...........  T  ...................................  ￿9  ......................................................... 
ANGI  ...........  .  ............................................................................................. 
MOS  ...........  .  ............  G  ......................  .  ..............  -  ...... C  G  .................................. 
Figure 2.  Nucleotide  sequence of downstream insertion junction in class II tumor V4D6.  The IL-3 promoter fragment  up to the novel HindllI 
site in V4D6 was cloned by inverse PCR (see Materials and Methods).  The sequence revealed the presence of a 5'LTR of an IAP inserted at position 
(-252) of the IL-3 transcription start. The U3 and R-region boundaries are indicated. Typical regulatory sequence motifs found are the glucocorticoid 
response  element ((;RE),  cAMP  response element  (CRE),  the  CAAT and TATA box in the U3-region, and three  repeats  of the duodecamer 
CTCTCTTGCTTC sequence and the poly(A) + site in the R-region as indicated. (*) Two positions in the enhancer 2 of relevance for bidirectional 
transcription (49). A comparison  for the LTR of the IAP in the Ib3/Hox2.4 gene of WEHI-3B (41, 50), for the angiotensinogen  IAP (33), and 
the rc-mos IAP (51) are given.  (- - -) Identical nucleotides;  (.  ￿9  .) gaps. 
ras-neo vector, but do not show the IL-3 insertion before the 
singular tumor formation (Fig.  1, compare lanes 4 and I2). 
In contrast, typical class I tumors are generated from the ras- 
expressing PB-3c subclones 8V4 and 15V4 after a long latency 
of 9-14 wk, but with a high tumor incidence of 80-100% 
under the same conditions (17, 23). 
Insertion of an Intracisternal A-particle (IAP)  1 in the IL-3 Pro- 
moter of the Class II Tumor  V4D6.  A more extensive anal- 
),sis of the rearrangement produced a restriction pattern com- 
patible with an IAP (32), an endogenous retroviral element, 
that had inserted into the IL-3 locus (data not shown). The 
double band detected in the dass II tumor line V4D6 after 
HindIII digestion indicated that this insertion was in prox- 
imity of the IL-3 promoter (Fig. 1, lane 13).  Cloning by in- 
1  Abbreviation used in this ~per: lAP, intracisternal  A-particle. 
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verse PCR after  HindlII digestion and circularization (see 
Materials and Methods) allowed the identification of the 5'LTR 
sequence of an IAP that had inserted at position (-252) of 
the IL-3 transcription start site (Fig. 2). The orientation was 
head-to-head with respect to the transcriptional orientation 
of the IL-3 gene. Analysis of the nucleotide sequence showed 
the presence of the typical IAP-LTR sequence motifs in the 
U3-region (see legend to Fig.  2).  Comparison with other 
IAP-LTRs revealed that the sequence of the U3- and R-region 
was almost identical to an IAP-LTR detected previously in 
the angiotensinogen locus (33). Interestingly, the 5'LTR of 
the V4D6-IAP was found to be inserted only 9 bp upstream 
of the previously described IAP-IL-3 insertion site detected 
in  WEHI-3B  (34),  an  IL-3-producing  myelomonocytic 
leukemia line, but differed in stretches of the R-region (Fig. 
2). From the SphI digestion (Fig.  1), and other restriction 
digestions (data not shown), the inserted element was esti- 
mated to be about 5 kb in size. Enhanced  IL-3  Gene  ~ansc@tion  in  Class II  Tumors. 
Assuming an IAP enhancer insertion mechanism, we searched 
for functional alteration at the transcriptional level. The rates 
of IL-3 gene transcription of class II tumor lines V4D6 and 
R56VT,  class I tumors, and the IL-3-dependent precursor 
lines were compared in a nuclear run-on assay. Relative to 
the actin signal as activity control, the signals for IL-3 tran- 
scription were indeed increased in the class II tumors V4D6 
and K56VT  over the levels detected in  the nonrearranged 
precursors PB-3c and R56 (Fig. 3, A and B) or the v-H-ras-ex- 
pressing lines V2 or R56V (Fig.  3, compare G  and H  with 
C and D). Furthermore, the rate of IL-3 gene transcription 
in class II tumors appeared to be higher than in the class I 
tumor lines V2D1  and 15V-T2  (Fig.  3, E  and F;  see also 
Fig. 6, A  and C). As expected, expression of v-H-ras from 
the ZIP-ras-neo vector leads to a dramatic increase in tran- 
scription signal for ras (Fig. 3, A  and B vs C and D). Poten- 
tial effects of the v-H-ras expression on IL-3 gene transcrip- 
tion are currently under investigation. Transcription of IL-6 
was included as a control for a cytokine of different chro- 
mosomal location which is already expressed in PB-3c cells, 
but is irrelevant for proliferation (our own unpublished data; 
see also Figs. 4 and 7). Taken together, these results indicate 
that the DNA rearrangement in class II tumors is associated 
with  an enhanced transcription of the IL-3 gene. 
IL-3 Expression of Class II Tumors Is Dominant in Somatic 
Cell Hybrids with PB-3c.  We have previously shown that the 
autocrine IL-3 expression of the class I tumor line V2D1 was 
recessive as it could be downregulated by somatic cell fusion 
with the nontumorigenic, IL-3-dependent parental line PB-3c 
(16).  Since the p21  ras expression levels were not affected, 
this experiment suggested the loss  of a negative regulator 
of IL-3 expression in autocrine tumor formation which could 
be supplied in trans by fusion with the untransformed PB-3c. 
It was therefore of interest to compare the effect of somatic 
cell fusion on the IL-3 expression of class II tumors. Class 
Figure 4.  ID3 mRNA expres- 
sion  in  somatic  cell  hybrids. 
Poly(A) +  enriched  RNA  from 
400/~g of total RNA were ex- 
tracted  from  the  indicated  cell 
lines, analyzed by Northern blot- 
ting,  and  hybridized  to  I1-3 
cDNA, I1-6 cDNA, and/3-actin 
(Materials and  Methods). 
I and II cell hybrids were generated between the IL-3-inde- 
pendent G418-resistant tumor cells of V2D1 or V4D6 and 
a hygromycin-resistant subline of PB-3c, respectively. After 
selection with G418 and hygromydn in the presence of IL-3, 
resistant hybrids, termed PB3c/V2D1 and PB3c/V4D6 were 
analyzed  for  IL-3  expression  by  Northern  blotting  of 
poly(A) + enriched RNA.  The results in Fig.  4  show that 
IL-3 expression of the class I tumor line V2D1  is reduced 
to  trace amounts in the hybrid PB3c/V2D1  (Fig.  4,  lanes 
3  and 4),  whereas IL-3 expression in the class II hybrid is 
only slightly reduced. Quantitation of fl-actin normalized 
IL-3 expression by storage phosphor technique indicated an 
approximately fourfold reduction in class II hybrid PB3c/ 
V4D6, whereas the signal in the class I hybrid PB3c/V2D1 
was nearly 20-fold reduced. In contrast, cell fusion had no 
significant effect on fl-actin or IL-6 expression.  The non- 
tumorigenic PB-3c do not express IL-3 mRNA, as indicated 
by Northern blotting (Fig. 4, lane I), and reverse PCR (data 
Figure  3.  Nuclear run-on analysis. The indicated cDNA probes, and 
lambda DNA as unspecific control, were spotted on nitrocellulose  filters 
and hybridized  to labeled nuclear  RNA isolated from 107 nuclei of the 
indicated  cell lines, as described.  PB-3c (A);  K56,  a subclone  of PB-3c 
(B); V2, ZIP-ras-neo-infected PB-3c (C); R56V, ZIP-ras-neo-infected R56 
(D); V2D1, class I tumor derived from V2 (E); 15V-T2, class I tumor de- 
rived from 15V4 (F); V4D6,  a class II tumor derived from ZIP-ras-neo 
infected PB-3c (G); and R56VT, a class II tumor derived from IL56V (H). 
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Dilutions  of  supernatants 
Mitogenic activity in supematants  of tumor and cell hybrids.  Figure  5. 
Cells were washed three times and resuspended in Ib3-free IMDM/10% 
FCS at 10  s cell/ml and incubated.  The supernatants  were taken after 3 d, 
sterile-filtered (0.2/zm diameter  pore size), and  tested in two dilutions 
for mitogenic activity on an IL-3-dependent subclone  of PB-3c. 
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the expression of v-H-ras in the still IL-3-dependent V2 line 
(Fig.  4, lane 2), as described previously (23).  Mitogenic ac- 
tivity in supernatants of the tumors and respective hybrids 
were tested in 1:5 and 1:10 dilution on an IL-3-responsive 
subline of PB-3c.  The results agree with the pattern of IL-3 
mRNA expression (Fig.  5) showing a reduction in the class 
II hybrid in comparison with the respective tumor, whereas 
the class I hybrid was at the background level of PB-3c.  To 
examine the effect of somatic cell fusion on IL-3 gene tran- 
scription, in particular whether a transcriptional turnoff  was 
responsible for the observed downregulation of IL-3 expres- 
sion in class I hybrids, both classes of tumors and the respec- 
tive  hybrid  lines  were  compared  in  a  nuclear  run-on 
experiment (Fig. 6). The rate of IL-3 gene transcription was 
examined using an IL-3 cDNA fragment and a nonoverlap- 
ping genomic fragment containing the transcription start up 
to the HindlII site in exon 1 of IL-3. Given the comparable 
levels of the 13-actin signal, almost similar rates of transcrip- 
tion  were  detected  in  V2D1  and  its  respective  hybrid 
PB3c/V2D1. The autoradiograms were analyzed by densito- 
metric scanning and the rates normalized to actin are given 
for comparison (Fig. 6). Taking the transcription rate detected 
by the IL-3 cDNA in the class I tumor V2D1  as  1.0,  the 
difference to the corresponding signal of 1.2 in the class I 
hybrid was considered to be insignificant. This suggested that 
the dramatic downregulation of IL-3 mRNA expression in 
class I hybrid PB3c/V2D1  (Fig. 4) was not due to a tran- 
scriptional turnoff (Fig. 6, A  and B), but appears to involve 
negative posttranscriptional regulation. In the class II hybrid 
PB3c/V4D6, however, a 35% reduction of the transcription 
rate compared with the class II tumor was observed (Fig. 
6, C and D). The rate of IL-3 gene transcription in the class 
II tumor was about fourfold higher than in the class I tumor. 
The 5'-IL-3 probe showed comparable results, yet at a two- 
to threefold higher level. The reason for this is unclear, but 
might involve a polarity effect of ILNA-polymerase II tran- 
scription in  the in vitro reaction. 
Class II Hybrids Proliferate  without  Exogenous IL-3 and Form 
Tumors Rap@  The pattern oflL-3 mRNA expression was 
also reflected in cell proliferation in vitro and tumorigenicity 
in syngeneic animals. The class I tumor V2D1 (Fig.  7, open 
triangles), the class II tumor V4D6 (Fig. 7, dosed triangles), 
and the dass II hybrid PB3c/V4D6 (Fig. 7, closed diamonds) 
grew in the absence of exogenous IL-3 in vitro and formed 
tumors in the animal within 4-6 wk (Fig.  7 and Table  1). 
In contrast, the class I hybrid PB-3c/V2D1 (Fig. 7, open dia- 
monds) required exogenous IL-3 for growth and showed par- 
tial or total tumor suppression in the animal, depending on 
whether 10  s or  106 cells were inoculated (Table  1).  PB-3c 
cells infected with a retrovirus conferring hygromycin resis- 
tance required exogenous IL-3 (Fig. 7, pentangles) and were 
nontumorigenic (Table 1). These results suggest that, in con- 
trast to the recessive class I tumor cells, the IL-3 rearrange- 
ment detected in class II tumor cells is associated with a dom- 
inant  tumor phenotype that could not be reverted by cell 
fusion. In support of this hypothesis, cell fusion of other class 
I tumor lines 15V-T2 and 8V4-T12 to PB-3c resulted in IL-3 
dependence of cell viability, whereas proliferation and via- 
bility of class II tumor lines R56VT and 22V4-T1 and their 
respective hybrids proved to be IL-3 independent (Table 2). 
Mitogenic activity could not always be detected in the super~ 
natants of all IL-3-independent cell lines correlating with 
the fact that the levels of IL-3 mRNA expression were low 
in these tumor lines (Table  2,  and data not  shown). 
Discussion 
Somatic cell fusion as a well-established tool in cancer re- 
search has helped to classify tumorigenic alterations into dom- 
Figure  6.  Comparison of Ib3 transcription  in tumors and cell hybrids 
by nuclear run-on assay. The assay was carried out as described (in Materials 
and Methods).  To detect the I1:3 transcription  rate, an Ib3 cDNA frag- 
ment and the 5'-Ib3 probe, a nonoverlapping  genomic I1:3 fragment con- 
taining the transcription  start and part of exon 1, were compared relative 
to the g-actin cDNA signal, whereas lambda DNA served as control for 
unspecific DNA binding. For comparison,  the relative transcriptional  ac- 
tivity is given after the intensities were quantltated by densitometric scan- 
ning, and normalized to the areas of the corresponding  actin signal. The 
activity of the IL-3 cDNA transcription  in the class I call line V2D1 was 
taken  as 1.0. 
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Figure  7.  IL-3-independent prolifcration of tumor and cell hybrids. The 
increase in the number of viable cells in the absence of exogenous  IL.3 
were compared  in an MTT assay (31) (see Materials and Methods).  The 
indicated  cells were washed  three  times and  resuspended  in  I1:3-free 
IMDM/10% FCS at 2  x  104 cells/m1 as triplicates in microtiter plates. 
At the indicated days, the MTT assay was performed. Class I tumor V2D1 
(open triangles); class I hybrid PB3c/V4D6 (open diamonds); class II tumor 
V4D6 (closed triangles); class II hybrid PB3c/V4D6 (closed diamonds); and 
PB-3c as control with I1:3 (open  pentang/e), or without 1I:3 (closedpentangle). Table  1.  Tumor Formation and Latency of Class I and II Somatic Cell Hybrids 
Cells 
Cell line  injected  2  4  6  8  10  12  17  26  42 
PB-3cH  10  s  0/5  0/5  0/5 
106  0/5  0/5  0/5 
V2D1  10  s  0/5  2/5  5/5 
10  6  0/5  3/5  5/5 
PB3c/V2D1  10  s  0/5  0/5  0/5 
106  0/5  0/5  0/5 
V4D6  10  s  0/5  5/5 
106  0/5  5/5 
PB3c/V4D6  10  s  0/5  0/5  5/5 
106  0/4  3/4  4/4 
wk 
0/5  0/5  0/5  0/5  0/5  0/5 
0/5  0/5  0/5  0/5  0/5  0/5 
0/5  0/5  0/5  0/5  0/5  0/5 
0/5  2/5  3/5  5/5 
Results given as number of tumors formed/number of animals injected. 
inant  and recessive lesions (11). Using this tool, we provide 
evidence that v-H-ras-mediated  tumor formation of IL-3-de- 
pendent PB-3c cells can occur by two different mechanisms, 
both of which allow the establishment  of an autocrine  IL-3 
loop. Class I tumors arise frequently, and show no detectable 
alteration in the vicinity of the IL-3 locus (Fig. 1). Although 
we cannot  exclude a more distant chromosomal alteration 
in class I tumors, the cell fusion experiments with the non- 
Table  2.  Effect of Somatic Cell Fusion on IL-3 Expression and Viability 
Viability  IL-3  IL-3  IL-3  gene 
Cell line  w/o  IL-3  mRNA  secretion  insertion 
% 
Parental  PB3c  0*  -  *  _  g  _  PI 
V2  1  (+)  -  - 
R56V  0  -  -  - 
Class  I  V2D1  92  +  +  +  +  +  +  - 
PB3c/V2D1  0  -  -  - 
15V-T2  80  +  -  - 
PB3c/15VT2  5  ND  -  ND 
8V4-T12  93  +  -  - 
PB3c/8V4T12  1  ND  -  ND 
Class II  V4D6  94  +  +  +  +  +  +  + 
PB3c/V4D6  88  +  +  +  +  + 
R56VT  93  +  +  +  + 
PB3c/R56VT  81  ND  +  ND 
22V4-T1  92  ( + )  -  + 
PB3c/22V4T1  93  ND  -  ND 
* By trypan blue color exclusion  after  18  h in IL-3 free IMDM/10%  FCS. 
by (polyA) + Northern blot or when indicated  (+) by reverse PCR. 
S Mitogenic activity  in supernatants. 
II By Southern blot hybridization. 
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istence of two different routes. Class I tumors appear to carry 
a recessive lesion that can be complemented by the precursor 
cell as the resulting cell hybrids showed loss of IL-3 expres- 
sion, IL-3 dependence in vitro,  and partial tumor suppres- 
sion in vivo. Class II tumors, however, arise rarely, and show 
an about 5-kb insertion in the IL-3 gene (Figs. 3 and 4 and 
Tables I and 2). The insertion is linked to a dominant altera- 
tion, since IL-3 expression is maintained in the class II hybrids, 
and rapid tumor formation is observed upon injection into 
syngeneic mice (Tables 1 and 2). In the class II tumor V4D6, 
cloning and sequencing identified the insertion of an IAP, 
an endogenous retroviral element, at position - 252 from the 
transcription start of IL-3 (Fig.  2).  Preliminary restriction 
analysis indicates the presence of IAP insertions also in the 
other class II tumors (data not shown). Nuclear run-on data 
show that this insertion is associated with an increased rate 
of transcription as compared with class I tumor cells or the 
IL-3-dependent precursor cells (Figs. 3 and 6). In agreement 
with the enhancer-type orientation, the major form of the 
IL-3 mRNA expressed is of normal size. The larger IL-3 tran- 
scripts detected in the class II tumor V4D6 do not represent 
IAP-IL-3 chimera (Fig. 3, lane 5), but normal unspliced IL-3 
mRNA precursor (data not shown). Somatic cell fusion of 
class II tumors appeared to reduce the IL-3 transcription rate 
approximately twofold (Fig.  6)  and  the cytoplasmic IL-3 
mRNA level by about fourfold (Fig. 4). The reason for this 
is unknown, but a certain reduction appears compatible with 
changing the ratio of rearranged to unaltered IL-3 alleles from 
1:1  to  1:3 upon cell hybridization. 
A functional equivalent to class II tumors has been described 
in a human B cell leukemia with t(5;14) translocation, which 
placed the IL-3 gene in the vicinity of the IgH enhancer (35). 
This translocation was associated with high serum levels of 
IL-3 which correlated with the number of leukemic cells in 
the course of the disease. In murine malignancies, the inser- 
tion of IAP was reported to be involved in the activation of 
the IL-3, IL-5, IL-6, GM-CSF, as well as the IL-2R and IL- 
6R receptor genes (34, 36-42). In some of these tumor lines, 
activating lesions in the myb or box2.4 genes are known to 
be present as well (40, 43). It has been observed that the overall 
transcriptional activity of IAPs is higher in tumor cells than 
in normal adult tissues (32).  In fact, transactivation of IAP- 
LTR reporter constructs by the oncogene products such as 
EIA, SV40 large-T antigen, and myc has been described (44). 
Most notably, the v-K-ras oncogene product enhanced the 
transcription rate of 5'IAP-LTR reporter constructs via a 
cAMP-responsive element (45).  This in vitro observation is 
of particular interest as it suggests a rationale for increasing 
IAP transposition events in ras-transformed PB-3c which be- 
come apparent as class II tumors in vivo. Stocking et al. (39) 
have observed that insertions into growth factor loci can occur 
spontaneously in vitro at a frequency of around two in 107 
murine cells, which could be increased 20-fold by retroviral 
insertion mutagenesis. It is therefore of importance to note 
that without v-H-ras, PB-3c is not tumorigenic, even when 
infected with retroviral control vectors conferring neomycin 
or hygromycin resistance (Table 1; 16, 23). The clonal origin 
of the class II tumors R56VT and 22V4-T1 from subclones 
without IL-3 alteration (Fig. 1), and the rarity of these tumors 
suggest that IL-3 gene rearrangement provides an alternative 
route to tumor formation in vivo.  It remains to be shown 
that the transcriptional activation is sufficient to explain the 
IL-3 autocrine loop in class II tumors, or that the v-H-ras 
oncogene is necessary as well by perturbing other regulatory 
functions. 
90% of tumors obtained from v-H-ras-expressing PB-3c 
cells are of the class I type that produce IL-3 without detect- 
able IL-3 gene rearrangement. Clonal precursor cells of class 
I tumors 8V4 and 15V4 repeatedly showed a high tumor in- 
cidence of 80-100%  (17). Recent data suggest that v-H-ras 
synergizes efficiently  with a premaliguant lesion in these cells 
(23).  Comparison of the IL-3 transcription rate in the ras- 
expressing class I precursor line V2 with the respective class 
I tumor line V2D1 (Fig.  3, B and D) indicates no increase 
upon tumor formation, yet, a striking difference in the amount 
of cytoplasmic IL-3 mRNA is observed (Fig. 4, lanes 2 and 
3). Cell fusion of the class I V2D1 with PB-3c, reduced the 
IL-3 mlkNA expression *20-fold to a level comparable with 
the precursor line V2 (Fig.  3, lane 4), but the rate of IL-3 
transcription was basically unaltered in the class I hybrid (Fig. 
6). Taken together, these data suggest that class I tumor for- 
mation may arise from the loss of a negative regulator of IL-3 
expression which is present in untransformed cells and which 
acts by a posttranscriptional mechanism. Since the tumor cells 
were hybridized to the parental cell line, effects of tissue-specific 
extinction do not apply.  This is supported by the fact that 
IL-3 expression could still be induced in class I somatic cell 
hybrids by treatment with calcium ionophore (Hirsch, H. H., 
unpublished data) as demonstrated for PB-3c and primary 
mast cells (18,  21).  As shown previously (16),  the level of 
p21 ms expression in the cell hybrids was unaltered (data not 
shown). Work in our laboratory indicated mRNA stabiliza- 
tion as an important posttranscriptional control element for 
the physiological IL-3 expression in PB-3c mast cells which 
may be increased upon the expression of ms oncogene (22, 
23). At this time, there is only one well-documented report 
that increased cytokine mRNA stability might be an onco- 
genic principle.  Schuler and Cole (46) have described a mono- 
cytic tumor line induced by the v-myc oncogene in which 
the lymphokine GM-CSF had an unusually slow decay rate. 
The mechanism was active in trans and involved the 3' un- 
translated region of GM-CSF containing the characteristic 
AUUUA motives also found in IL-3 (29, 47) which are in- 
volved in the rapid mRNA decay of cytokines and proto- 
oncogenes (48). With the precursor cells at hand, the molec- 
ular elucidation of the tumorigenic lesion in PB-3c class I 
tumors should be possible and provide new insights into the 
posttranscriptional regulation of IL-3 expression. Whereas 
v-H-ms expression appears  to be necessary for the progres- 
sion to either class of autocrine tumors, the role of the on- 
cogene in maintenance of the tumor phenotype is still open. 
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